Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aptorum Group Ltd    APM   KYG6096M1069


News SummaryMost relevantAll newsOfficial PublicationsSector news

Aptorum : Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
05/15/2019 | 09:01pm EDT
  • Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is launching its flagship fund - Pyrinas US Healthcare Real Estate Fund 1 SP – to acquire and develop co-working space and incubator facilities for the life sciences sector in the United States;
  • Opportunity to invest in one of the most vibrant real estate sectors in the U.S. that is currently not available in most of the Asia Pacific countries. A great geographical and asset class diversification of Asia Pacific real estate investment;
  • Tap into the life sciences sector that generally has one of the highest barriers to entry amongst different industries;
  • Experienced and unique advisory/management team in this specific sector with established operation track record.

Aeneas Capital Limited (“ACL”) and Pyrinas Real Estate Management Limited (“Pyrinas”), based in Hong Kong, is launching a US$120m innovative closed-ended property fund – Pyrinas US Healthcare Real Estate Fund 1 SP – with a geographical focus on selected cities across North America. Supported by the ecosystem of its affiliated company, Aptorum Group (Nasdaq: APM), the fund’s key investment objective is to acquire and redevelop real estate into shared laboratories and incubator facilities for life science sector start-ups, one of the most vibrant sectors in North America. The fund will focus its investments in primarily four North America mandated cities (namely Cambridge, Boston, Houston, and San Francisco in the United States and Toronto in Canada).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515005721/en/

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Mr. Matthew Wong, Chief Executive Officer of Pyrinas, commented, “These cities have been selected in view of several crucial factors that we believe are best positioned to take advantage of the robust growth in the life science industry. The fund will focus on acquisition and development of real estate suitable for the healthcare and life science sector, particularly in operating laboratories with a co-working space model. We are seeing increasingly robust demand for space by life science companies and start-ups, who are encouraged by the rapidly growing venture capital investment market in North America.”

The fund is targeting a launch size of up to US$120 million with a targeted return of 15-19% per annum (Net IRR) over a period of four years with one-year extension. Pyrinas is currently in discussions with a number of institutional investors and collaborative partners.

Together with its affiliated company Aptorum Group Limited (Nasdaq: APM) and Aeneas Capital, the fund also aims to nurture medical research, the development of intellectual property, and collaboration between scientists, researchers, investors, and industry participants; while providing real estate solutions that foster an ecosystem for collegial interactions among industry, investors, government and academia.

The fund is targeted for institutional and professional investors only and subject to restrictions in certain jurisdictions.

About the Group

Pyrinas Real Estate Management Limited (”Pyrinas”), the real estate arm of Aeneas Group and an affiliate of Aptorum Group, was established in 2018. Pyrinas currently is managing two laboratory facilities and one clinic facility in Hong Kong. For more information about Pyrinas, please visit www.pyrinasgroup.com.

Aeneas Group Limited, the parent company of Aeneas Capital Limited (“ACL”), is a multi-disciplinary financial institution with cross border capabilities and technology services. For more information about Aeneas Group Limited, please visit www.aeneasgroup.com.

Aptorum Group Limited (Nasdaq : APM) is a biopharmaceutical company currently developing a portfolio of therapeutic candidates and medical devices, and is dedicated to developing and commercializing its portfolio of technologies to tackle unmet medical needs observed globally. For more information about Aptorum Group Limited, please visit www.aptorumgroup.com.

Disclaimer. The information contained in this press release should not be construed as an offer of, or a solicitation for an investment in, securities or any other financial instrument in any jurisdiction.

© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on APTORUM GROUP LTD
07/11SMART PHARMA TOKEN (SMPT) DEBUTS ITS : Global Blockchain Cryptocurrencies Tradin..
07/08APTORUM GROUP : 's subsidiary Smart Pharma announces Smart Pharma token (SMPT) t..
05/22APTORUM : to Be Newly Added to MSCI HK Micro Cap Index
05/15APTORUM : Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co..
05/06APTORUM : Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeuti..
04/24APTORUM : USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Cap..
04/24APTORUM : Establishes Smart Pharma to Focus on Computational Repurposed Drug Dis..
04/24APTORUM : Smart Pharma announces launch of its asset backed Smart Pharma token (..
04/24APTORUM GROUP LIMITED : Announces Repurchase of USD13,500,000 Outstanding Conver..
04/15APTORUM : Reports 2018 Fiscal Year Financial Results and Business Update
More news
Financials (USD)
Sales 2019 1,00 M
EBIT 2019 -11,9 M
Net income 2019 -19,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -29,6x
P/E ratio 2020 -26,9x
Capi. / Sales2019 465x
Capi. / Sales2020 225x
Capitalization 465 M
Duration : Period :
Aptorum Group Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 28,50  $
Last Close Price 16,00  $
Spread / Highest target 119%
Spread / Average Target 78,1%
Spread / Lowest Target 37,5%
EPS Revisions
Ian Huen Chief Executive Officer & Executive Director
Darren Lui President, Chief Business Officer & Director
Sabrina Khan Chief Financial Officer
Clark Cheng Chief Medical Officer & Executive Director
Keith Chan Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341
PFIZER-20.62%194 582